At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 576 enrolled
Drug / intervention
GSK233705 12.5mcg +5 moredrug
Likely dose
GSK233705 12.5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
In Brief
A Phase 2 clinical trial evaluating GSK233705 12.5mcg, GSK233705 25mcg, and 4 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 576 participants across 88 sites in 14 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesArgentina, Bulgaria, Canada, Chile, Germany, Hungary, Netherlands, Philippines, Romania, South Africa, South Korea, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartMay 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedMay 12, 2008
Enrollment StartMay 16, 2008
Primary CompletionDec 22, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.1 years ago
Interventions
GSK233705 12.5mcgdrug
Once daily via dry powder inhaler
GSK233705 25mcgdrug
once daily via dry powder inhaler
GSK233705 50mcgdrug
Once daily via dry powder inhaler
GSK233705 100mcgdrug
Once daily via dry powder inhaler
GSK233705 200mcgdrug
Once daily via dry powder inhaler
Placebodrug
Once daily via dry powder imhaler